Forbes June 24, 2024
A whopping 1 in 8 U.S. adults have taken GLP-1 drugs like Wegovy and Ozempic for weight loss and related conditions. Their popularity and efficacy have sparked a prescription-writing frenzy in recent years, leaving both medications on the FDA’s drug shortage list since May 2023.
But even when the supply rebounds, access to these drugs will remain out of reach for the majority of Americans. That’s because brand-name GLP-1 drugs range from $11,000 to $16,000 a year, prices that are unaffordable for most people.
Attempts to control prices through legislation face significant hurdles, both in the divided halls of Congress and in the courts, where determined legal challengers await. Senator Bernie Sanders, chair of the Senate Health Committee, hopes that...
Today's Sponsors
Today's Sponsor